Innoviva Inc
NASDAQ:INVA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.43
20.72
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one INVA stock under the Base Case scenario is 18.77 USD. Compared to the current market price of 19.68 USD, Innoviva Inc is Overvalued by 5%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Innoviva Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for INVA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Innoviva Inc
Balance Sheet Decomposition
Innoviva Inc
Current Assets | 400.6m |
Cash & Short-Term Investments | 260.6m |
Receivables | 91.1m |
Other Current Assets | 48.9m |
Non-Current Assets | 831m |
Long-Term Investments | 507.7m |
PP&E | 3.3m |
Intangibles | 302.3m |
Other Non-Current Assets | 17.7m |
Current Liabilities | 223.8m |
Accounts Payable | 4.2m |
Accrued Liabilities | 20.8m |
Other Current Liabilities | 198.8m |
Non-Current Liabilities | 339.3m |
Long-Term Debt | 256m |
Other Non-Current Liabilities | 83.3m |
Earnings Waterfall
Innoviva Inc
Revenue
|
352.7m
USD
|
Cost of Revenue
|
-42.6m
USD
|
Gross Profit
|
310.2m
USD
|
Operating Expenses
|
-148.9m
USD
|
Operating Income
|
161.3m
USD
|
Other Expenses
|
-96.7m
USD
|
Net Income
|
64.6m
USD
|
Free Cash Flow Analysis
Innoviva Inc
USD | |
Free Cash Flow | USD |
INVA Profitability Score
Profitability Due Diligence
Innoviva Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Innoviva Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
INVA Solvency Score
Solvency Due Diligence
Innoviva Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Innoviva Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INVA Price Targets Summary
Innoviva Inc
According to Wall Street analysts, the average 1-year price target for INVA is 18.36 USD with a low forecast of 18.18 USD and a high forecast of 18.9 USD.
Dividends
Current shareholder yield for INVA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 5 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). ANORO ELLIPTA is a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with an LABA, VI. TRELEGY ELLIPTA (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA, and LABA.
Contact
IPO
Employees
Officers
The intrinsic value of one INVA stock under the Base Case scenario is 18.77 USD.
Compared to the current market price of 19.68 USD, Innoviva Inc is Overvalued by 5%.